$KYMR

Kymera Therapeutics, Inc.

Runway:5 mo

NasdaqMarket cap: —CIK 0001815442

Upcoming catalysts

0 surfaced

No catalysts surfaced for KYMR yet.

KT-474/Placebo

Healthy Volunteer

KT-413

Non Hodgkin Lymphoma

KT-621

Atopic Dermatitis

KT-253

Myeloid Malignancies

KT-579

Healthy Participants

KT-333

Non Hodgkin Lymphoma (NHL)

NCT	Drug	Phase	Status	Primary completion
NCT07323654	KT-621	Phase 2	Recruiting	2027-12-01
NCT07217015	KT-621	Phase 2	Recruiting	2027-06-01
NCT07412288	KT-579	Phase 1	Recruiting	2026-12-01
NCT06945458	KT-621	Phase 1	Completed	2025-11-10
NCT06673667	KT-621	Phase 1	Completed	2025-04-23
NCT05225584	KT-333	Phase 1	Completed	2025-03-03
NCT05775406	KT-253	Phase 1	Completed	2024-12-18
NCT05233033	KT-413	Phase 1	Completed	2023-07-28
NCT04772885	KT-474/Placebo	Phase 1	Completed	2022-10-20
NCT04440410	—	—	Completed	2021-03-24